Abstract:The zinc-containing histone deacetylase enzyme HDAC7 is emerging as an important regulator of immunometabolism and cancer. Here, we exploit a cavity in HDAC7, filled by Tyr303 in HDAC1, to derive new inhibitors. Phenacetyl hydroxamates and 2-phenylbenzoyl hydroxamates bind to Zn2+ and are 50–2700-fold more selective inhibitors of HDAC7 than HDAC1. Phenylbenzoyl hydroxamates are 30–70-fold more potent HDAC7 inhibitors than phenacetyl hydroxamates, which is attributed to the benzoyl aromatic group interacting with Phe679 and Phe738. Phthalimide capping groups, including a saccharin analogue, decrease rotational freedom and provide hydrogen bond acceptor carbonyl/sulfonamide oxygens that increase inhibitor potency, liver microsome stability, solubility, and cell activity. Despite being the most potent HDAC7 inhibitors to date, they are not selective among class IIa enzymes. These strategies may help to produce tools for interrogating HDAC7 biology related to its catalytic site.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01967?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01967</a>.Additional experimental procedures, figures and tables describing modelling for alternative docked ligand poses in HDAC7, chemical synthesis, and compound characterization (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_001.pdf">PDF</a>)Figure 3 docking pose for compound 5a (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_002.pdb">PDB</a>)Figure 4 docking pose for compound 5a (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_003.pdb">PDB</a>)Figure 4 docking pose for compound 22 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_004.pdb">PDB</a>)Figure 4 docking pose for compound 31 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_005.pdb">PDB</a>)Figure S1 docking pose for compound 5a (without water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_006.pdb">PDB</a>)Figure S1 docking pose for compound 5a (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_007.pdb">PDB</a>)Figure S2 docking pose for compound 15 (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_008.pdb">PDB</a>)Figure S3 docking pose for compound 22 (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_009.pdb">PDB</a>)Figure S3 docking pose for compound 30 (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_010.pdb">PDB</a>)Figure S3 docking pose for compound 31 (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_011.pdb">PDB</a>)SMILES strings of all compounds used for docking (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_012.csv">CSV</a>)This article has not yet been cited by other publications.

Docking Study of HDAC Implication for Benzamide Inhibitors Binding Mode

Identification of Ligand Features Essential for HDACs Inhibitors by Pharmacophore Modeling.

Investigating Potential Cancer Therapeutics: Insight into Histone Deacetylases (HDACs) Inhibitions

HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates

Discovery of Novel Small Molecule HDAC1, 2, 3 Inhibitors -- Combined Receptor-Based and Ligand-Based Virtual Screening Strategy

Computational Exploration of Zinc Binding Groups for Hdac Inhibition

Structure-based screening of FDA-approved drugs identifies potential histone deacetylase 3 repurposed inhibitor: molecular docking and molecular dynamic simulation approaches

3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment.

Exploring different classification-dependent QSAR modelling strategies for HDAC3 inhibitors in search of meaningful structural contributors

Exploring Inhibitor Release Pathways in Histone Deacetylases Using Random Acceleration Molecular Dynamics Simulations

Inhibition And Mechanism Of Hdac8 Revisited

Structure-Function Analysis of the Conserved Tyrosine and Diverse Π-Stacking among Class I Histone Deacetylases: A QM (DFT)/MM MD Study

Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors

Molecular docking and molecular dynamic simulations of inhibitor ZJ0777 and CIE binding to acetohydroxyacid synthases

3d-Qsar And Molecular Docking Studies On Benzotriazoles As Antiproliferative Agents And Histone Deacetylase Inhibitors

Structure-based Optimization of Click-Based Histone Deacetylase Inhibitors

Development of Hydroxamate-Based Histone Deacetylase Inhibitors of Bis-Substituted Aromatic Amides with Antitumor Activities.

Key structural requirements of benzamide derivatives for histone deacetylase inhibition: design, synthesis and biological evaluation

Do Biological Activities of Selective Histone Deacetylase 6 (HDAC6) Inhibitors Rely on the Modification of Cap Group?

Identification of novel leads as potent inhibitors of HDAC3 using ligand-based pharmacophore modeling and MD simulation

The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker